Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
NCT07662031Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tovecimig in colorectal cancer (CRC), sponsored by Washington University School of Medicine. Primary endpoint: Overall Response Rate at 12 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tovecimig
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07662031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662031.